Shree Ganesh [SGRL] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Shree Ganesh Remedies Ltd. wins in 5 metrics, Sun Pharmaceutical Industries Ltd. wins in 14 metrics, with 0 ties. Sun Pharmaceutical Industries Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Shree Ganesh Remedies Ltd. | Sun Pharmaceutical Industries Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 37.03 | 36.73 | Sun Pharmaceutical Industries Ltd. |
| Price-to-Book Ratio | 4.36 | 5.15 | Shree Ganesh Remedies Ltd. |
| Debt-to-Equity Ratio | 24.45 | 6.68 | Sun Pharmaceutical Industries Ltd. |
| PEG Ratio | -0.86 | 3.59 | Sun Pharmaceutical Industries Ltd. |
| EV/EBITDA | 18.54 | 23.61 | Shree Ganesh Remedies Ltd. |
| Profit Margin (TTM) | 17.99% | 19.21% | Sun Pharmaceutical Industries Ltd. |
| Operating Margin (TTM) | 19.25% | 26.17% | Sun Pharmaceutical Industries Ltd. |
| EBITDA Margin (TTM) | 19.25% | 26.17% | Sun Pharmaceutical Industries Ltd. |
| Return on Equity | 15.89% | 15.08% | Shree Ganesh Remedies Ltd. |
| Return on Assets (TTM) | 12.02% | 11.87% | Shree Ganesh Remedies Ltd. |
| Free Cash Flow (TTM) | $74.69M | $119.44B | Sun Pharmaceutical Industries Ltd. |
| Dividend Yield | N/A | 0.97% | N/A |
| 1-Year Return | -2.45% | 7.10% | Sun Pharmaceutical Industries Ltd. |
| Price-to-Sales Ratio (TTM) | 6.66 | 7.05 | Shree Ganesh Remedies Ltd. |
| Enterprise Value | $6.74B | $3,783.37B | Sun Pharmaceutical Industries Ltd. |
| EV/Revenue Ratio | 6.70 | 6.66 | Sun Pharmaceutical Industries Ltd. |
| Gross Profit Margin (TTM) | 70.00% | 80.96% | Sun Pharmaceutical Industries Ltd. |
| Revenue per Share (TTM) | $78 | $237 | Sun Pharmaceutical Industries Ltd. |
| Earnings per Share (Diluted) | $14.09 | $45.46 | Sun Pharmaceutical Industries Ltd. |
| Beta (Stock Volatility) | 0.19 | 0.11 | Sun Pharmaceutical Industries Ltd. |
Shree Ganesh Remedies Ltd. vs Sun Pharmaceutical Industries Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Shree Ganesh Remedies Ltd. | -5.26% | -12.23% | -1.17% | 19.76% | 24.86% | 27.80% |
| Sun Pharmaceutical Industries Ltd. | -0.09% | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Shree Ganesh Remedies Ltd. | -2.45% | 64.10% | 49.51% | 1,719.55% | 1,719.55% | 1,719.55% |
| Sun Pharmaceutical Industries Ltd. | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
Performance & Financial Health Analysis: Shree Ganesh Remedies Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | SGRL | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹6.70B | ₹3.88T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 4,488 | 3,903,142 |
| 90 Day Avg. Volume | 4,536 | 3,253,866 |
| Last Close | ₹568.85 | ₹1,806.00 |
| 52 Week Range | ₹381.10 - ₹665.00 | ₹1,548.00 - ₹1,916.60 |
| % from 52W High | -14.46% | -5.77% |
| All-Time High | ₹950.05 (Jul 22, 2024) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -40.12% | -7.87% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.22% | 0.14% |
| Quarterly Earnings Growth | -0.43% | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | 0.18% | 0.19% |
| Operating Margin (TTM) | 0.19% | 0.26% |
| Return on Equity (TTM) | 0.16% | 0.15% |
| Debt to Equity (MRQ) | 24.45 | 6.68 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹119.59 | ₹324.46 |
| Cash per Share (MRQ) | ₹26.25 | ₹115.87 |
| Operating Cash Flow (TTM) | ₹337.14M | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹230.68M | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.97% |
| Last 12-Month Dividend | ₹0.00 | ₹16.50 |
Valuation & Enterprise Metrics Analysis: Shree Ganesh Remedies Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | SGRL (Apr 24, 2026) | SUNPHARMA (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 37.03 | 36.73 |
| Forward P/E | N/A | 29.48 |
| PEG Ratio | -0.86 | 3.59 |
| Price to Sales (TTM) | 6.66 | 7.05 |
| Price to Book (MRQ) | 4.36 | 5.15 |
| Market Capitalization | ||
| Market Capitalization | ₹6.70B | ₹3.88T |
| Enterprise Value | ₹6.74B | ₹3.78T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.70 | 6.66 |
| Enterprise to EBITDA | 18.54 | 23.61 |
| Risk & Other Metrics | ||
| Beta | 0.19 | 0.11 |
| Book Value per Share (MRQ) | ₹119.59 | ₹324.46 |
Financial Statements Comparison: Shree Ganesh Remedies Ltd. vs Sun Pharmaceutical Industries Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | SGRL (2025) | SUNPHARMA (2025) |
|---|---|---|
| Revenue/Sales | 1.07B | 520.41B |
| Cost of Goods Sold | 361.73M | 121.98B |
| COGS % of Revenue | 34.0% | 23.4% |
| Gross Profit | 703.31M | 398.44B |
| Gross Margin | 66.0% | 76.6% |
| Research & Development | 2.65M | N/A |
| Operating Income (EBIT) | 301.91M | 125.81B |
| Operating Margin | 28.3% | 24.2% |
| EBITDA | 420.76M | 167.25B |
| EBITDA Margin | 39.5% | 32.1% |
| Pre-Tax Income | 312.68M | 137.52B |
| Pre-Tax Income % of Revenue | 29.4% | 26.4% |
| Income Tax | 81.99M | 27.72B |
| Income Tax % of Revenue | 7.7% | 5.3% |
| Net Income (Profit) | 230.68M | 109.65B |
| Profit Margin | 21.7% | 21.1% |
Balance Sheet & Liquidity Metrics
| Metric | SGRL (2025) | SUNPHARMA (2025) |
|---|---|---|
| Cash & Equivalents | 99.43M | 102.69B |
| Total Current Assets | 775.75M | 526.24B |
| Total Current Assets % of Revenue | 72.8% | 101.1% |
| Total Current Liabilities | 161.82M | 181.94B |
| Total Current Liabilities % of Revenue | 15.2% | 35.0% |
| Long-Term Debt | 296.08M | 3.58B |
| Long-Term Debt % of Revenue | 27.8% | 0.7% |
| Total Shareholders Equity | 1.45B | 724.86B |
| Retained Earnings | 1.10B | 578.62B |
| Retained Earnings % of Revenue | 103.1% | 111.2% |
| Property, Plant & Equipment | 31.57M | 100.36B |
Cash Flow Statement Comparison
| Metric | SGRL (2025) | SUNPHARMA (2025) |
|---|---|---|
| Operating Cash Flow | 337.14M | 110.84B |
| Operating Cash Flow % of Revenue | 31.7% | 21.3% |
| Capital Expenditures | -231.76M | -20.68B |
| Free Cash Flow | 74.69M | 119.44B |
| FCF Margin | 7.0% | 23.0% |
| Debt Repayment | N/A | -43.44B |
| Common Stock Repurchase | N/A | -29.00B |
Short Interest & Institutional Ownership Analysis
| Metric | SGRL | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 12.84M | 2.40B |
| Float Shares | 3.09M | 1.07B |
| % Held by Insiders | 75.92% | 55.62% |
| % Held by Institutions | 0.00% | 28.69% |
| % Held by Public | 24.08% | 15.69% |
Dividend Analysis & Yield Comparison: Shree Ganesh Remedies Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | SGRL | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹16.50 |
| Last 12-Month Dividend Yield | N/A | 0.97% |
| 3-Year Avg Annual Dividend | ₹0.33 | ₹17.33 |
| 3-Year Avg Dividend Yield | 0.15% | 0.51% |
| 3-Year Total Dividends | ₹1.00 | ₹52.00 |
| Ex-Dividend Date | Sep 07, 2023 | Feb 05, 2026 |